Dr Ryan Hamdy Mbchb
Dr Ryan Hamdy Mbchb
Registered General Practitioner
Galderma
Galderma S.A. is a Swiss global pharmaceutical company specialising exclusively in dermatology. It develops, manufactures and commercialises products across dermatological skincare, therapeutic dermatology and injectable aesthetics for medical and aesthetic applications worldwide. The company partners closely with healthcare professionals and invests in scientific research and education.Overview
Founded Year: 1981
Founder: Jointly established by L’Oréal and Nestlé
Purpose: To advance dermatology for every skin story by delivering evidencebased solutions, innovative products and professional support spanning skin health, aesthetics and therapeutic care.
Governing Body
Organisation Name: Galderma S.A.
Company Status: Publicly traded pharmaceutical company (listed on SIX Swiss Exchange)
Regulatory Status: Operates under international pharmaceutical regulations and product approvals enforced by health authorities (e.g., FDA, EMA) for therapeutic and aesthetic products
Industry Standing: A leading pureplay dermatology company with global reach, extensive scientific R&D, and a mature portfolio of therapeutic, skincare and aesthetic brands recognised by healthcare professionals worldwide.
Eligibility Criteria
Who Can Apply:
Requirements:
Restrictions:
Judging Criteria
Evaluation Factors:
Categories
Available Categories:
Dermatological SkincareTherapeutic DermatologyInjectable Aesthetics
Accreditation Requirements
Inspection Required:
Documentation Required:
Compliance Standards:
Regulatory marketing authorisations in each countr...Good Manufacturing Practice (GMP) standards for pr...
Sources:
Verification Process
Public Register:
Certificate Validation Method:
Sources:
Renewal & Compliance
Renewal Frequency:
CPD Requirements:
Audit Process:
Sources:
Benefits
Reputation: Galderma is recognised internationally as a specialist dermatology company with established brands such as Cetaphil, Restylane, Dysport and Sculptra, widely used in clinical practice and by patients.
Patient Trust Impact: Healthcare professionals often recommend Galderma products, and patient trust is reinforced through clinical evidence, regulatory approvals and physician endorsements.
Patient Safety Impact
Mechanisms of Protection:
Products undergo rigorous clinical trials and regulatory review before approval for therapeutic and aesthetic use.Ongoing pharmacovigilance monitors safety and efficacy in post‑marketing environments.
Limitations:
Not a professional certification or clinical credential for practitioners.Product safety and outcomes vary by individual patient and treatment context.
Comparison with Other Bodies
Comparable Entities:
Allergan Aesthetics (AbbVie)Galderma competitors within dermatology and aesthetics markets
Key Differences:
Galderma is a pure‑play dermatology company focused solely on skin health and aesthetics, whereas some competitors operate broader pharmaceutical portfolios.Unique integrated dermatology strategy spanning prescription, skincare and aesthetic segments.
Industry Recognition
Media Mentions:
Galderma’s IPO and financial performance have been covered by major financial news outlets.Industry press highlights product launches, clinical trial outcomes and global expansion initiatives.
Endorsements:
Credibility Signals:
Presence in over 90 countries and longstanding brand recognition.Investment in extensive clinical R&D and partnerships with healthcare professionals.
Government Regulation Status
Statutory Backing:
Regulated By: Subject to regulatory oversight by health authorities (e.g., FDA in USA, EMA in Europe) for it's products.
Legal Status: Publicly traded pharmaceutical corporation operating under applicable national and international regulations.
